Cellosaurus 260F9 (CVCL_J908)
Cell line name | 260F9 | |
---|---|---|
Accession | CVCL_J908 | |
Resource Identification Initiative | To cite this cell line use: 260F9 (RRID:CVCL_J908) | |
Comments | Group: Patented cell line. Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8488. Biotechnology: The monoclonal antibody produced by this hybridoma was conjugated to a ricin chain A to produce 260F9-rRTA which was evaluated in two phase 1 clinical trials which were not pursued due to severe toxicity of the conjugate (DOI=10.3390/antib1010039). Monoclonal antibody isotype: IgG1. Monoclonal antibody target: Human breast/ovarian cancer 55 kDa antigen. | |
Species of origin | Mus musculus (Mouse) (NCBI Taxonomy: 10090) | |
Hierarchy | Parent: CVCL_2199 (Sp2/0-Ag14) Children:
| |
Category | Hybridoma | |
Publications | Patent=US4753894 Patent=US4938948 Patent=US4956453 Patent=US5629197 DOI=10.3390/antib1010039 | |
Cross-references | ||
Cell line collections (Providers) | ATCC; HB-8488 | |
Encyclopedic resources | Wikidata; Q54583674 | |
Entry history | ||
Entry creation | 11-Feb-2013 | |
Last entry update | 21-Mar-2023 | |
Version number | 8 |